Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Last trade$3.04
Day change+$0.04 (+1.33%)
Day range$2.91 – $3.22
Volume904,454
Market cap$312M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$311.65M
Price / earnings
—
Price / book
2.45×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.23×
Profitability
Earnings per share
-$1.66
Return on assets
-104.42%
Return on equity
-135.5%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.7×
Quick ratio
4.7×
Cash ratio
2.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$156.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LRMR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.35M
$6.09M
$4.65M
$4.57M
$4.42M
$4.64M
$4.56M
$4.35M
Research and development
$28M
$25.03M
$59.37M
$44.93M
$23.37M
$26.55M
$26.74M
$13.92M
Total operating expenses
$34.35M
$31.12M
$64.02M
$49.5M
$27.79M
$31.19M
$31.29M
$18.26M
Operating income
-$34.35M
-$31.12M
-$64.02M
-$49.5M
-$27.79M
-$31.19M
-$31.29M
-$18.26M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$32.78M
-$29.61M
-$62.5M
-$47.71M
-$26.18M
-$29.28M
-$28.82M
-$15.5M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$32.78M
-$29.61M
-$62.5M
-$47.71M
-$26.18M
-$29.28M
-$28.82M
-$15.5M
Net income attributable to common shareholders
-$32.78M
-$29.61M
-$62.5M
-$47.71M
-$26.18M
-$29.28M
-$28.82M
-$15.5M
EBITDA
-$34.29M
-$31.05M
-$63.93M
-$49.41M
-$27.71M
-$31.1M
-$31.22M
-$18.19M
Basic earnings per share
-$0.30
-$0.31
-$0.73
-$0.61
-$0.41
-$0.46
-$0.45
-$0.24
Diluted earnings per share
-$0.30
-$0.31
-$0.73
-$0.61
-$0.41
-$0.46
-$0.45
-$0.24
Recent news
Company coverage with links to the original publishers.
Larimar stock has declined 22.7% over the past four weeks and is now in oversold territory with an RSI reading of 28.31, suggesting a potential trend reversal. Analysts have raised earnings estimates by 5% over the last 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential near-term price appreciation.
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics regarding its nomlabofusp drug candidate for Friedreich's Ataxia. The company's stock fell significantly after disclosing serious safety concerns—anaphylaxis in 7 participants in September 2025 and in 10 of 43 patients by June 2026—despite characterizing the data as 'positive' in press releases.
Larimar Therapeutics (NASDAQ: LRMR), a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The offering is expected to close on February 27, 2026, with proceeds to be used for development of nomlabofusp and general corporate purposes. J.P. Morgan and Guggenheim Securities are serving as joint bookrunning managers.
Larimar Therapeutics priced an upsized underwritten public offering of 20 million shares at $5.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to support development of nomlabofusp for Friedreich's ataxia and for general corporate purposes. The offering is expected to close on February 27, 2026, with J.P. Morgan and Guggenheim Securities as joint bookrunning managers.
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.